Amgen, Inc., Sanofi SA (ADR)-Regeneron Pharmaceuticals Inc PCSK9 Inhibitors

March 17, 2015 1:43 PM

2 0

The pharmaceutical industry may soon see a drastic change in the treatment of heart diseases as it readies up to launch nuanced yet expensive PCSK9 inhibitors for treating cardiovascular diseases. These drugs are likely to be received well by the market, given the fact that there is considerable, yet indecisive, evidence that establishes that the PCSK9-inhibiting drugs reduce the risk of serious cardiovascular events by 50%.

The research, collected from considerably smaller studies sponsored separately by Amgen, Inc. (NASDAQ:AMGN) and Sanofi SA (ADR) (NYSE:SNY) as well as its partner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), was presented at the annual meeting of the American College of Cardiology.

Read more

To category page